Skip to content

filings.toolsA Dark Vector Cognition product

Item 6. Exhibits

4K characters. Original on sec.gov · Markdown

Item 6. Exhibits

(a) Exhibits


Exhibit Number						Description
10.1*						Amendment No. 2 to Master Agreement, dated as of March 7 , 202 4 , by and between Regeneron Pharmace uticals , Inc. (the "Registrant") and Alnylam Pharmaceuticals, Inc.
31.1						Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
31.2						Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
32						Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350.
101						Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"): (i) the Registrant's Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023; (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2024 and 2023; (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2024 and 2023; (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023; and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Certain confidential portions of this Exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of all confidential portions of this Exhibit that were omitted to the SEC upon its request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


									REGENERON PHARMACEUTICALS, INC.

Date:			May 2, 2024						By:			/s/ Christopher Fenimore

												Christopher Fenimore
												Senior Vice President, Finance and
												Chief Financial Officer
												(Duly Authorized Officer)

Previous: Item 5. Other Information